Scholarlink

Background <p>Canine leishmaniosis (CanL) is endemic in Italy and is an important veterinary and public health concern. Integrated preventive strategies combining vaccination and vector control are recommended in endemic areas, and field data supporting the safety and effectiveness of this concurrent use are limited.</p> Methods <p>A longitudinal field study conducted on Favignana Island (Sicily, Italy) evaluated the concurrent use of a vaccine (LETIFEND<sup>®</sup>, Leti) and sandfly repellent collar (SCALIBOR<sup>®</sup>, MSD Animal Health). Client-owned dogs (154) were prescreened by clinical examination, serology, quantitative polymerase chain reaction (qPCR) and serological testing (SNAP<sup>®</sup>4Dx<sup>®</sup> Plus, IDEXX). <i>Leishmania</i>-negative dogs (62) were enrolled in the study, vaccinated, fitted with a deltamethrin-impregnated sandfly repellent collar, and monitored every 6 months for 24&#xa0;months (2 transmission seasons). Follow-up evaluations included clinical examination, serological testing (SNAP<sup>®</sup> Leish<sup>®</sup> Test, IDEXX), and conjunctival swab qPCR; sera were stored for subsequent indirect immunofluorescence antibody testing (IFAT). After 12&#xa0;months, dogs that remained negative received a booster vaccination and replacement collar.</p> Results <p>The proportion of dogs positive for CanL in the prescreen was 12.3% (19/154). Two dogs in the enrolled group (3.22%, 2/62) developed clinical signs compatible with CanL and tested positive (SNAP<sup>®</sup>Leish<sup>®</sup>,IDEXX) during the study. IFAT testing of enrolled dogs found low antibody titres in nine additional clinically healthy dogs corresponding to a cumulative infection incidence of 14.5% and an incidence density of 0.61% per dog-month. No local or systemic adverse reactions associated with the combined preventive protocol were recorded.</p> Conclusions <p>Concurrent vaccination (LETIFEND<sup>®</sup>, Leti) and preventive collar administration (SCALIBOR<sup>®</sup>, MSD Animal Health) resulted in no adverse events, although there was a low incidence of clinical CanL and seroconversion over two consecutive transmission seasons. These findings support the use of integrated preventive strategies to limit the development of clinical disease in dogs living in endemic areas.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Canine leishmaniosis on Favignana Island: a prospective observational study on infection dynamics, clinical outcomes and field safety in dogs receiving both vaccination (LETIFEND®) and an antifeeding collar (SCALIBOR®)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月30日

查看全文
  • Valentina Foglia Manzillo,
  • Gaetano Oliva,
  • Germano Castelli,
  • Federica Bruno,
  • Roberto Rosenthal,
  • Serena Montagnaro,
  • Ines Balestrino,
  • Claudia La Rocca,
  • Liliana Colombo,
  • Manuela Gizzarelli

摘要

Background

Canine leishmaniosis (CanL) is endemic in Italy and is an important veterinary and public health concern. Integrated preventive strategies combining vaccination and vector control are recommended in endemic areas, and field data supporting the safety and effectiveness of this concurrent use are limited.

Methods

A longitudinal field study conducted on Favignana Island (Sicily, Italy) evaluated the concurrent use of a vaccine (LETIFEND®, Leti) and sandfly repellent collar (SCALIBOR®, MSD Animal Health). Client-owned dogs (154) were prescreened by clinical examination, serology, quantitative polymerase chain reaction (qPCR) and serological testing (SNAP®4Dx® Plus, IDEXX). Leishmania-negative dogs (62) were enrolled in the study, vaccinated, fitted with a deltamethrin-impregnated sandfly repellent collar, and monitored every 6 months for 24 months (2 transmission seasons). Follow-up evaluations included clinical examination, serological testing (SNAP® Leish® Test, IDEXX), and conjunctival swab qPCR; sera were stored for subsequent indirect immunofluorescence antibody testing (IFAT). After 12 months, dogs that remained negative received a booster vaccination and replacement collar.

Results

The proportion of dogs positive for CanL in the prescreen was 12.3% (19/154). Two dogs in the enrolled group (3.22%, 2/62) developed clinical signs compatible with CanL and tested positive (SNAP®Leish®,IDEXX) during the study. IFAT testing of enrolled dogs found low antibody titres in nine additional clinically healthy dogs corresponding to a cumulative infection incidence of 14.5% and an incidence density of 0.61% per dog-month. No local or systemic adverse reactions associated with the combined preventive protocol were recorded.

Conclusions

Concurrent vaccination (LETIFEND®, Leti) and preventive collar administration (SCALIBOR®, MSD Animal Health) resulted in no adverse events, although there was a low incidence of clinical CanL and seroconversion over two consecutive transmission seasons. These findings support the use of integrated preventive strategies to limit the development of clinical disease in dogs living in endemic areas.

Graphical Abstract